Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7499537 | 0.80 | HTR1A (0.52) | HTR1ADRD2DRD3 | |
| SCHEMBL323149 | 0.80 | DRD2 (0.56) | HTR1ADRD2DRD3 | |
| SCHEMBL2465607 | 0.80 | HTR1A (0.49) | HTR1ADRD2DRD3 | |
| SCHEMBL7963983 | 0.79 | DRD2 (0.46) | HTR1ADRD2DRD3 | |
| SCHEMBL2787499 | 0.79 | HTR1A (0.47) | HTR1ADRD2DRD3 | |
| SCHEMBL5666715 | 0.78 | HTR1A (0.40) | HTR1A | |
| SCHEMBL28195182 | 0.78 | HTR1A (0.47) | HTR1AHTR2CDRD2DRD3 | |
| SCHEMBL28405635 | 0.77 | CHRNB4 (0.45) | HTR1A | |
| SCHEMBL28286740 | 0.76 | HTR1A (0.49) | HTR1ADRD2DRD3 | |
| SCHEMBL1538935 | 0.76 | DRD2 (0.52) | HTR1ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106103432-B | Substituted thiazole or oxazole P2X7 receptor antagonist | 阿克萨姆股份公司 | 2019-10-18 | — | — | CN | disclosed |
| US-10167281-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2019-01-01 | — | — | US | disclosed |
| EP-3102573-B1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM SPA (IT) | 2018-04-11 | — | — | EP | disclosed |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-10-05 | — | — | US | disclosed |
| US-9718812-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | AXXAM S.P.A. (IT) | 2017-08-01 | — | — | US | disclosed |
| US-20170008883-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2017-01-12 | — | — | US | disclosed |
| EP-3102573-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.p.A. (IT) | 2016-12-14 | — | — | EP | disclosed |
| CN-106103432-A | The thiazole being replaced or azoles P2X7 receptor antagonist | 阿克萨姆股份公司 | 2016-11-09 | — | — | CN | disclosed |
| WO-2015118019-A9 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2016-04-21 | — | — | WO | disclosed |
| WO-2015118019-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2015-08-13 | — | — | WO | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| WO-2010021681-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-02-25 | — | — | WO | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167281-B2 | Substituted thiazole or oxazole P2X7 receptor antagonists | P2RX7, P2RX1, P2RX2 | HTR1A 504/4885HTR2C 621/4885DRD2 2770/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | HTR1A 1/4885HTR2C 19/4885DRD2 59/4885 |
| US-20170283409-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX2 | HTR1A 504/4885HTR2C 621/4885DRD2 2770/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | HTR1A 3475/4885HTR2C 3981/4885DRD2 3870/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | HTR1A 3394/4885HTR2C 3915/4885DRD2 4136/4885 |
| US-20170008883-A1 | SUBSTITUTED THIAZOLE OR OXAZOLE P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX1, P2RX2 | HTR1A 495/4885HTR2C 622/4885DRD2 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.